Heron Therapeutics is trading 6.21% down in pre-market at $0.46 after its August 10, 2026 second-quarter report missed revenue and earnings expectations.
- Total net revenue was $37.7 million versus the $42.19 million consensus estimate.
- Management withdrew full-year 2026 guidance because of uncertainty around generic competition and strategic alternatives.
- The earnings release was scheduled for August 10, 2026, making it the clearest catalyst for the pre-market decline.